Table 5.
Stability studies
| Compound | Nominal concentration (ng/mL) | Freeze/Thaw between −80°C and RT | Autosampler at 10°C | Benchtop at RT | Longterm stability | Stock solution stability | |||
|---|---|---|---|---|---|---|---|---|---|
| 1 F/T | 2 F/T | 3 F/T | 24h | 72h | 4h | 51 days | 7 months | ||
| Abacavir | 300 | 100.9 (2.6) | 101.2 (3.9) | 101.8 (4.5) | 101.4 (1.4) | 105.4 (0.6) | 94.0 (8.3) | 90.6 (5.6) | 112.8 (3.5) |
| 4000 | 99.8 (4.9) | 106.2 (2.3) | 108.0 (2.3) | 100.0 (0.2) | 103.8 (0.5) | 95.3 (4.6) | 93.7 (9.3) | 105.3 (2.0) | |
| Bictegravir | 300 | 100.7 (5.2) | 98.6 (8.1) | 96.6 (3.5) | 104.1 (5.3) | 103.2 (1.7) | 90.2 (5.0) | 94.6 (1.1) | 106.7 (4.6) |
| 4000 | 100.3 (8.4) | 99.2 (5.2) | 97.3 (5.2) | 101.8 (2.6) | 101.0 (1.2) | 90.0 (5.6) | 103.4 (5.5) | 98.2 (4.6) | |
| Cabotegravir | 300 | 99.7 (1.6) | 100.3 (1.8) | 101.1 (1.2) | 100.4 (0.9) | 103.2 (2.4) | 90.1 (3.4) | 93.9 (9.7) | 108.5 (6.5) |
| 4000 | 98.3 (5.3) | 109.0 (3.0) | 107.8 (3.0) | 102.7 (1.4) | 107.3 (1.5) | 94.1 (5.1) | 102.2 (3.2) | 107.5 (2.4) | |
| Dolutegravir | 300 | 98.2 (0.6) | 99.4 (1.9) | 98.9 (1.4) | 99.9 (0.7) | 101.9 (0.7) | 92.5 (5.3) | 96.0 (3.8) | 108.0 (7.2) |
| 4000 | 100.1 (3.7) | 107.8 (3.9) | 108.7 (1.1) | 101.5 (0.6) | 104.5 (1.5) | 93.4 (3.4) | 94.8 (8.3) | 101.6 (2.0) | |
| Doravirine | 300 | 98.6 (9.8) | 98.6 (7.7) | 99.0 (1.7) | 101.1 (2.6) | 102.5 (0.3) | 91.9 (11.2) | 96.9 (7.8) | 98.2 (4.1) |
| 4000 | 97.1 (5.7) | 105.4 (3.2) | 104.0 (3.2) | 97.8 (0.1) | 101.5 (1.9) | 93.0 (4.4) | 93.5 (9.9) | 99.2 (2.2) | |
| Emtricitabine | 300 | 101.7 (7.5) | 94.4 (2.3) | 104.4 (10.8) | 99.1 (4.6) | 108.1 (2.8) | 95.2 (12.1) | 92.5 (5.4) | 101.7 (8.0) |
| 4000 | 99.4 (8.2) | 98.3 (1.4) | 108.4 (6.0) | 101.9 (4.0) | 111.3 (3.5) | 97.9 (6.9) | 98.2 (8.1) | 106.3 (3.0) | |
| Lamivudine | 300 | 99.7 (1.1) | 103.0 (4.9) | 107.0 (5.9) | 101.2 (0.8) | 103.1 (1.9) | 89.4 (3.2) | 97.0 (1.5) | 100.1 (2.1) |
| 4000 | 100.5 (4.5) | 104.9 (3.1) | 111.6 (3.1) | 104.1 (1.7) | 110.5 (0.6) | 90.5 (4.4) | 93.9 (9.6) | 101.8 (2.4) | |
| Raltegravir | 300 | 98.6 (5.5) | 98.6 (4.8) | 98.9 (4.3) | 101.1 (0.2) | 103.4 (1.3) | 93.8 (6.6) | 93.2 (7.7) | 103.2 (6.1) |
| 4000 | 99.9 (5.2) | 109.7 (3.5) | 108.1 (3.5) | 99.6 (1.3) | 103.1 (1.1) | 94.0 (3.4) | 90.3 (8.9) | 101.9 (3.5) | |
| Tenofovir | 300 | 106.1 (2.4) | 103.3 (6.7) | 112.3 (2.9) | 109.4 (1.4) | 111.5 (3.9) | 93.5 (4.5) | 94.4 (7.7) | 93.1 (1.1) |
| 4000 | 93.3 (1.0) | 101.1 (5.0) | 109.1 (4.9) | 100.1 (5.0) | 93.1 (5.7) | 98.9 (5.9) | 99.5 (3.6) | 90.6 (2.7) | |
Data are mean percent recoveries (CV%). N=3 for each stability level. N=5 for long-term stability studies.